PPARα-independent arterial smooth muscle relaxant effects of PPAR α agonists

PPAR Research

Volumn , Issue , 2012, Pages

  Silswal, Neerupma ^a   Parelkar, Nikhil K ^a   Wacker, Michael J ^a   Badr, Mostafa ^b   Andresen, Jon ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 4 AMINOPYRIDINE; GEMFIBROZIL; GLIBENCLAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHORBOL DIBUTYRATE; PIRINIXIC ACID;

ANIMAL EXPERIMENT; AORTA; ARTERY MUSCLE; ARTICLE; ENDOTHELIUM; MIDDLE CEREBRAL ARTERY; MOUSE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; SMOOTH MUSCLE RELAXATION;

EID: 84867313495     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/302495     Document Type: Article

References (56)

1. Van Raalte D. H., Li M., Pritchard P. H., Wasan K. M., Peroxisome proliferator-activated receptor (PPAR)- α: a pharmacological target with a promising future. Pharmaceutical Research 2004 21 9 1531 1538 2-s2.0-21644436821 10.1023/B:PHAM.0000041444.06122.8d (Pubitemid 41184380)
2. Issemann I., Green S., Cloning of novel members of the steroid hormone receptor superfamily. Journal of Steroid Biochemistry and Molecular Biology 1991 40 13 263 269 2-s2.0-0025932630 10.1016/0960-0760(91)90191-7
3. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 6294 645 650 2-s2.0-0025132245 10.1038/347645a0 (Pubitemid 20356241)
4. Braissant O., Foufelle F., Scotto C., Daua M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α-β and-γ in the adult rat. Endocrinology 1996 137 1 354 366 2-s2.0-0030047806 10.1210/en.137.1.354 (Pubitemid 26005011)
5. Lee S. S. T., Pineau T., Drago J., Lee E. J., Owens J. W., Kroetz D. L., Fernandez- Salguero P. M., Westphal H., Gonzalez F. J., Targeted disruption of the α isoform of the peroxisome proliferator- activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Molecular and Cellular Biology 1995 15 6 3012 3022 2-s2.0-0028997684
6. Inoue I., Shino K., Noji S., Awata T., Katayama S., Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochemical and Biophysical Research Communications 1998 246 2 370 374 2-s2.0-0032546485 10.1006/bbrc.1998.8622 (Pubitemid 28412605)
7. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P., Delerive P., Fadel A., Chinetti G., Fruchart J. C., Najib J., Maclouf J., Tedgui A., Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. Nature 1998 393 6687 790 793 2-s2.0-0032565868 10.1038/31701 (Pubitemid 28299490)
8. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J. P., Staels B., Auwerx J., Laville M., Vidal H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997 46 8 1319 1327 2-s2.0-0030747895 (Pubitemid 27315281)
9. Gottlicher M., Widmark E., Li Q., Gustafsson J. A., Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 1992 89 10 4653 4657 2-s2.0-0026551309 10.1073/pnas.89.10.4653
10. Yu K., Bayona W., Kallen C. B., Harding H. P., Ravera C. P., McMahon G., Brown M., Lazar M. A., Differential activation of peroxisome proliferator-activated receptors by eicosanoids. The Journal of Biological Chemistry 1995 270 41 23975 23983 2-s2.0-0028802627 10.1074/jbc.270.41.23975
11. Devchand P. R., Keller H., Peters J. M., Vazquez M., Gonzalez F. J., Wahli W., The PPAR α -leukotriene B4 pathway to inflammation control. Nature 1996 384 6604 39 43 2-s2.0-0029661982 10.1038/384039a0 (Pubitemid 26374579)
12. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. The Journal of Biological Chemistry 1997 272 6 3406 3410 2-s2.0-0031013395 10.1074/jbc.272.6. 3406 (Pubitemid 27066837)
13. Gonzalez F. J., Peters J. M., Cattley R. C., Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor. Journal of the National Cancer Institute 1998 90 22 1702 1709 2-s2.0-0032545018 (Pubitemid 28539089)
14. Lemberger T., Saladin R., Vázquez M., Assimacopoulos F., Staels B., Desvergne B., Wahli W., Auwerx J., Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. The Journal of Biological Chemistry 1996 271 3 1764 1769 2-s2.0-0030060358 10.1074/jbc.271.3.1764 (Pubitemid 26028664)
15. Lemberger T., Staels B., Saladin R., Desvergne B., Auwerx J., Wahli W., Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids. The Journal of Biological Chemistry 1994 269 40 24527 24530 2-s2.0-0028003839 (Pubitemid 24311697)
16. Rubins H. B., Robins S. J., Collins D., The veterans affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. American Journal of Cardiology 1996 78 5 572 575 2-s2.0-0030237563 (Pubitemid 126658600)
17. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G., Wilt T. J., Wittes J., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The New England Journal of Medicine 1999 341 6 410 418 2-s2.0-0033527030 10.1056/NEJM199908053410604 (Pubitemid 29362514)
18. Rubins H. B., Robins S. J., Collins D., Nelson D. B., Elam M. B., Schaefer E. J., Faas F. H., Anderson J. W., Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Archives of Internal Medicine 2002 162 22 2597 2604 2-s2.0-0037049366 10.1001/archinte.162. 22.2597 (Pubitemid 35453499)
19. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V., Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. The New England Journal of Medicine 1987 317 20 1237 1245 2-s2.0-0023232216 (Pubitemid 17147964)
20. Manninen V., Elo M. O., Frick M. H., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Maenpaa H., Malkonen M., Manttari M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjoblom T., Nikkila E. A., Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. Journal of the American Medical Association 1988 260 5 641 651 2-s2.0-0023726344
21. Keech A., Simes R. J., Barter P., Best J., Scott R., Taskinen M. R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y. A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005 366 9500 1849 1861 2-s2.0-28044452217 10.1016/S0140-6736(05)67667-2 (Pubitemid 41690113)
22. Robinson J. G., Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. Current Atherosclerosis Reports 2007 9 1 64 71 2-s2.0-33846159487 10.1007/BF02693930 (Pubitemid 46075740)
23. Calkin A. C., Cooper M. E., Jandeleit-Dahm K. A., Allen T. J., Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 2006 49 4 766 774 2-s2.0-33644823630 10.1007/s00125-005-0102-6 (Pubitemid 43357552)
24. Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C., Danni O., Thiemermann C., Fantozzi R., Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR- α agonist WY14643. Free Radical Biology and Medicine 2006 41 4 579 589 2-s2.0-33746051675 10.1016/j.freeradbiomed.2006.04.030 (Pubitemid 44080506)
25. Okayasu T., Tomizawa A., Suzuki K., Manaka K. I., Hattori Y., PPAR α activators upregulate eNOS activity and inhibit cytokine-induced NF- κ B activation through AMP-activated protein kinase activation. Life Sciences 2008 82 15-16 884 891 2-s2.0-41149095864 10.1016/j.lfs.2008.02.002
26. Wang Y., Wang Y., Yang Q., Yan J. T., Zhao C., Cianflone K., Wang D. W., Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells. Atherosclerosis 2006 187 2 265 273 2-s2.0-33745567557 10.1016/j.atherosclerosis.2005.09.008 (Pubitemid 43977770)
27. Li A. C., Binder C. J., Gutierrez A., Brown K. K., Plotkin C. R., Pattison J. W., Valledor A. F., Davis R. A., Willson T. M., Witztum J. L., Palinski W., Glass C. K., Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR α β / δ and γ Journal of Clinical Investigation 2004 114 11 1564 1576 2-s2.0-10044271620 10.1172/JCI200418730 (Pubitemid 40385547)
28. Tabernero A., Schoonjans K., Jesel L., Carpusca I., Auwerx J., Andriantsitohaina R., Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacology 2002 2 1, article 10 2-s2.0-0037700107
29. Deplanque D., Gelé P., Pétrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J. C., Cecchelli R., Staels B., Duriez P., Bordet R., Peroxisome proliferator-activated receptor- α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. Journal of Neuroscience 2003 23 15 6264 6271 2-s2.0-0038720453 (Pubitemid 36875628)
30. Nakagawa K., Holla V. R., Wei Y., Wang W. H., Gatica A., Wei S., Mei S., Miller C. M., Dae R. C., Price E., Zent R., Pozzi A., Breyer M. D., Guan Y., Falck J. R., Waterman M. R., Capdevila J. H., Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. Journal of Clinical Investigation 2006 116 6 1696 1702 2-s2.0-33745197144 10.1172/JCI27546
31. Suardíaz M., Estivill-Torrús G., Goicoechea C., Bilbao A., Rodríguez de Fonseca F., Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 2007 133 13 99 110 2-s2.0-36249015507 10.1016/j.pain.2007.03.008 (Pubitemid 350138314)
32. González-Yanes C., Serrano A., Bermúdez-Silva F. J., Hernández-Dominguez M., Páez-Ochoa M. A., Rodríguez De Fonseca F., Sánchez-Margalet V., Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. American Journal of Physiology 2005 289 5 E923 E929 2-s2.0-27144462551 10.1152/ajpendo.00555.2004 (Pubitemid 41504394)
33. 2+induced p38 MAP kinase activation. EMBO Reports 2004 5 2 161 166 2-s2.0-1642487129 10.1038/sj.embor.7400072 (Pubitemid 38401195)
34. Gardner O. S., Dewar B. J., Earp H. S., Samet J. M., Graves L. M., Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. The Journal of Biological Chemistry 2003 278 47 46261 46269 2-s2.0-0344443788 10.1074/jbc.M307827200 (Pubitemid 37452196)
35. Gardner O. S., Dewar B. J., Graves L. M., Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Molecular Pharmacology 2005 68 4 933 941 2-s2.0-25144519803 10.1124/mol.105.012260 (Pubitemid 41345784)
36. Phelps L. E., Peuler J. D., Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil. Journal of Smooth Muscle Research 2010 46 3 125 142 2-s2.0-77956134224 10.1540/jsmr.46.125
37. Liu A., Yang J., Huang X., Xiong J., Wong A. H. H., Chang L., Dai R., Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs. Vascular Pharmacology 2012 56 3-4 168 175 2-s2.0-84862809430 10.1016/j.vph.2012.01.003
38. Andresen J. J., Shafi N. I., Durante W., Bryan R. M., Effects of carbon monoxide and heme oxygenase inhibitors in cerebral vessels of rats and mice. American Journal of Physiology 2006 291 1 H223 H230 2-s2.0-33745740067 10.1152/ajpheart.00058.2006
39. Bryan R. M. Jr., You J., Phillips S. C., Andresen J. J., Lloyd E. E., Rogers P. A., Dryer S. E., Marrelli S. P., Evidence for two-pore domain potassium channels in rat cerebral arteries. American Journal of Physiology 2006 291 2 H770 H780 2-s2.0-33746815591 10.1152/ajpheart.01377.2005 (Pubitemid 44175084)
40. Parelkar N. K., Silswal N., Jansen K., Vaughn J., Bryan R. M., Andresen J., 2,2,2-Trichloroethanol activates a nonclassical potassium channel in cerebrovascular smooth muscle and dilates the middle cerebral artery. Journal of Pharmacology and Experimental Therapeutics 2010 332 3 803 810 2-s2.0-77349121037 10.1124/jpet.109.162313
41. 2+ in arterial smooth muscle cells and elicits vasocontraction. American Journal of Physiology 2011 300 6 H2016 H2026 2-s2.0-79958041018 10.1152/ajpheart.01011.2010
42. Brown P. J., Stuart L. W., Hurley K. P., Lewis M. C., Winegar D. A., Wilson J. G., Wilkison W. O., Ittoop O. R., Willson T. M., Identification of a subtype selective human PPAR α agonist through parallel-array synthesis. Bioorganic and Medicinal Chemistry Letters 2001 11 9 1225 1227 2-s2.0-0035821394 10.1016/S0960-894X(01)00188-3 (Pubitemid 32406090)
43. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., Herman Z. S., Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. International Journal of Clinical Pharmacology and Therapeutics 1998 36 6 345 349 2-s2.0-0031813989 (Pubitemid 28271555)
44. Berger A., Roberts M. A., Unraveling Lipid Metabolism with Microarrays 2005 New York, NY, USA Marcel Dekker
45. 2+ signals and insulin secretion by PPAR α ligands in mouse pancreatic islets of Langerhans. Journal of Endocrinology 2009 200 2 127 138 2-s2.0-67449139093 10.1677/JOE-08-0397
46. Jiménez R., Sánchez M., Zarzuelo M. J., Romero M., Quintela A. M., López-Sepúlveda R., Galindo P., Gómez-Guzmán M., Haro J. M., Zarzuelo A., Pérez-Vizcaíno F., Duarte J., Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor β agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. Journal of Pharmacology and Experimental Therapeutics 2010 332 2 554 561 2-s2.0-76749129634 10.1124/jpet.109.159806
47. Ali F. Y., Davidson S. J., Moraes L. A., Traves S. L., Paul-Clark M., Bishop-Bailey D., Warner T. D., Mitchell J. A., Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR β FASEB Journal 2006 20 2 326 328 2-s2.0-33644883024 10.1096/fj.05-4395fje (Pubitemid 46671159)
48. Akbiyik F., Ray D. M., Gettings K. F., Blumberg N., Francis C. W., Phipps R. P., Human bone marrow megakaryocytes and platelets express PPAR γ and PPAR γ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004 104 5 1361 1368 2-s2.0-4444363344 10.1182/blood-2004-03-0926 (Pubitemid 39166512)
49. + channels in cultured vascular smooth muscle cells. Circulation Research 1994 74 3 471 476 2-s2.0-0028054989 (Pubitemid 24064197)
50. + channel-mediated responses of the basilar artery. Stroke 2002 33 6 1692 1697 2-s2.0-0036281514 10.1161/01.STR.0000016966.89226.67 (Pubitemid 34619980)
51. Goyal R., Mittal A., Chu N., Shi L., Zhang L., Longo L. D., Maturation and the role of PKC-mediated contractility in ovine cerebral arteries. American Journal of Physiology 2009 297 6 H2242 H2252 2-s2.0-72249095398 10.1152/ajpheart.00681.2009
52. Lagaud G., Gaudreault N., Moore E. D. W., Van Breemen C., Laher I., Pressure-dependent myogenic constriction of cerebral arteries occurs independently of voltage-dependent activation. American Journal of Physiology 2002 283 6 H2187 H2195 2-s2.0-0036889524 (Pubitemid 35345918)
53. Pucci M. L., Tong X., Miller K. B., Guan H., Nasjletti A., Calcium- and protein kinase C-dependent basal tone in the aorta of hypertensive rats. Hypertension 1995 25 4 752 757 2-s2.0-0028934886
54. Agrawal B., Kopeck J., Kränzlin B., Rohmeiss P., Pill J., Gretz N., Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats. Nephrology Dialysis Transplantation 1998 13 2 333 339 2-s2.0-0031965235 (Pubitemid 28062193)
55. Assmann G., Schulte H., The Prospective Cardiovascular Munster study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. American Journal of Cardiology 1987 59 14 9G 17G 2-s2.0-0023161561 (Pubitemid 17085539)
56. Kojda G., Mayer B., Therapeutic Importance of Nitrovasodilators Nitric Oxide 2000 Berlin, Germany Springer